Literature DB >> 2890857

Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis.

A M Prieur1, M T Kaufmann, C Griscelli, J M Dayer.   

Abstract

Interleukin-1 (IL-1) activity and inhibition were studied in serum and urine from nine patients with systemic juvenile chronic arthritis (S-JCA). In afebrile patients IL-1 activity was normal or high. Serum from two afebrile S-JCA patients taken during a period of severe disease activity had an enhancing effect on the activity of exogenous IL-1. Secondary amyloidosis subsequently developed in one of these patients. In contrast, in febrile patients' serum and urine IL-1 activity was low, apparently reflecting the presence of a strong inhibitor of IL-1 activity measured by the inhibition of prostaglandin E2 production by synovial cells. This inhibition was greatest at the time of peak temperature, suggesting the possibility of feedback regulation during fever. This novel identification in S-JCA of a specific IL-1 inhibitor that competes at the IL-1 receptor level may be an important step in the understanding of the pattern of fever and the evaluation of disease in patients with S-JCA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890857     DOI: 10.1016/s0140-6736(87)91854-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

1.  Protective effect of recombinant human IL-1Ra on CCl4-induced acute liver injury in mice.

Authors:  Run-Zhi Zhu; Di Xiang; Chao Xie; Jing-Jing Li; Jian-Jun Hu; Hong-Lin He; Yun-Sheng Yuan; Jin Gao; Wei Han; Yan Yu
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  Movement of a falciparum malaria protein through the erythrocyte cytoplasm to the erythrocyte membrane is associated with lysis of the erythrocyte and release of gametes.

Authors:  I A Quakyi; Y Matsumoto; R Carter; R Udomsangpetch; A Sjolander; K Berzins; P Perlmann; M Aikawa; L H Miller
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

3.  Alternative activation in systemic juvenile idiopathic arthritis monocytes.

Authors:  Claudia Macaubas; Khoa D Nguyen; Ariana Peck; Julia Buckingham; Chetan Deshpande; Elizabeth Wong; Heather C Alexander; Sheng-Yung Chang; Ann Begovich; Yue Sun; Jane L Park; Kuang-Hung Pan; Richard Lin; Chih-Jian Lih; Erin M Augustine; Carolyn Phillips; Andreas V Hadjinicolaou; Tzielan Lee; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2011-12-28       Impact factor: 3.969

4.  Selective and early increase of IL-1 inhibitors, IL-6 and cortisol after elective surgery.

Authors:  F Di Padova; C Pozzi; M J Tondre; R Tritapepe
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

5.  Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.

Authors:  C Gabay; M F Smith; D Eidlen; W P Arend
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

6.  Cytokines in childhood rheumatic diseases.

Authors:  P Woo
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

7.  Serum cytokine changes in systemic vasculitis.

Authors:  G E Grau; P Roux-Lombard; C Gysler; C Lambert; P H Lambert; J M Dayer; L Guillevin
Journal:  Immunology       Date:  1989-10       Impact factor: 7.397

Review 8.  Interleukin-1 function and role in rheumatic disease.

Authors:  Georg Schett; Jean-Michel Dayer; Bernhard Manger
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

9.  Live Borrelia burgdorferi preferentially activate interleukin-1 beta gene expression and protein synthesis over the interleukin-1 receptor antagonist.

Authors:  L C Miller; S Isa; E Vannier; K Georgilis; A C Steere; C A Dinarello
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients.

Authors:  Sebastian Niedźwiecki; Tomasz Stepień; Krzysztof Kuzdak; Henryk Stepień; Roman Krupiński; Daniel Seehofer; Nada Rayes; Frank Ulrich
Journal:  Langenbecks Arch Surg       Date:  2007-12-07       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.